Skip to main content
Premium Trial:

Request an Annual Quote

Orchid BioSciences to Open U.K. SNP Scoring Facility

NEW YORK, Oct. 19 - Orchid BioSciences announced Thursday it is establishing Orchid BioSciences Europe in Oxford, U.K, a wholly owned European subsidiary, which will open an Oxford-based SNP scoring and genetic diversity analysis facility for the European market.    

Orchid intends the Oxford facility to operate in a similar capacity to its current MegaSNPatron facility in Princeton N.J., which is capable of producing over 100,000 SNP scores per day.

 

 

“One of the rationales for doing the facility here is that we have a big opportunity in terms of collaborative relationships” with European pharma companies, said Christopher Ashton, vice president and managing director of Orchid BioSciences Europe. “It will build additional capacity, and the closer to the market, the better.”

Orchid Europe is now in the final stages of choosing laboratory space in the Oxford area, then plans to install a SNPStream 25K system at the facility and have an initial SNPstream machine up and running by the second quarter of next year, Ashton said. The company plans to ramp up to 100,000 SNP scores per day, then to begin multiplexing both at the sample preparation and the SNPstream end so it can eventually increase its daily production to millions of SNP scores. 

 

Orchid Europe does not yet have any partners lined up to begin SNP scoring and analysis in Europe, “but we’re in all sorts of discussions with a number of the top-tier pharmas over here, and in Europe, with middle-tier pharma companies, there’s more of a predisposition to license out their genotyping needs, “ Ashton said. The European facility will cater to these middle-tier pharma companies as well as biotech companies.

Orchid's only currently operational 25K SNPstream working in Europe is one at Smithkline’s U.K facility, which it installed in October 1999.

San Diego, Calif.-based Sequenom, which says its high-throughput MassArray SNP screening devices can perform up to 40,000 SNPs per day, has recently sold its system to the U.K.’s Sanger Center and the GSF -National Research Center for Environment and Health, a German governmental research institution.

  

 

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.